๐Ÿงช Beta โ€” BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs tamarixetin

Mechanistic comparison of isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from and tamarixetin based on molecular target overlap from BindingDB and ChEMBL binding affinity data.

8
Shared Targets
28%
Jaccard Similarity
28%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.

Evidence Comparison

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside [Supplementary Concept] from
โ€”
Evidence Score
300
PubMed Studies
View full profile โ†’
tamarixetin
โ€”
Evidence Score
26
PubMed Studies
View full profile โ†’

Target Overlap

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and tamarixetin share 8 molecular targets based on binding affinity data from BindingDB (Kd/IC50 โ‰ค 10 ยตM) and ChEMBL. A Jaccard index of 0.276 means 28% of the combined target set is bound by both compounds. The IDF-weighted score of 0.280 accounts for non-specific binding to metabolic enzymes.

Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.

Frequently Asked Questions

What do isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and tamarixetin have in common?
isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and tamarixetin share 8 molecular targets with a Jaccard similarity of 28%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and tamarixetin be combined?
isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside and tamarixetin share 8 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside or tamarixetin?
In the BiohacksAI corpus: isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside has 300 PubMed-indexed studies, tamarixetin has 26 studies.

Related Comparisons

Similar to isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside

isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs withaferin9 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs Hesperidin11 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs Kaempferols10 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs Kaempferols18 targetsisorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside vs diosmetin4 targets

Similar to tamarixetin

tamarixetin vs Withania3 targetstamarixetin vs isopimpinellin2 targetstamarixetin vs rocaglamide2 targetstamarixetin vs pyrrolidine2 targetstamarixetin vs naphthazalin2 targets
View full isorhamnetin-3-O-beta-D-glucopyranosyl-(1-3)-alpha-L-rhamnopyranosyl-(1-6)-beta-D-galactopyranoside profile โ†’View full tamarixetin profile โ†’Browse all substances โ†’